약물 발견 시장에서의 글로벌 인공지능(AI) – 2031년까지의 산업 동향 및 예측

약물 발견 시장 분석 및 규모에서의 인공지능(AI)

약물 발견 시장에서 인공지능(AI)은 기하급수적 성장을 계속하며 최신 방법과 기술을 활용하여 제약 연구에 혁명을 일으키고 있습니다. 고급 알고리즘과 데이터 분석을 통해 AI는 약물 식별 및 최적화 프로세스를 가속화하여 시간과 비용을 크게 줄입니다. 예측 모델링, 가상 스크리닝 및 표적 식별에 적용하면 약물 개발 효율성이 향상되어 질병 퇴치에 획기적인 진전이 있을 것으로 기대됩니다.                               

약물 발견 시장 규모에서 글로벌 인공지능(AI)은 2023년에 9억 3,224만 달러로 평가되었으며, 2031년까지 1,40914만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지 예측 기간 동안 CAGR은 5.30%입니다. 이는 시장 가치를 나타냅니다. 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화

시장 정의

약물 발견 분야의 인공지능(AI)은 고급 알고리즘을 활용하여 방대한 데이터 세트를 분석하고, 분자 상호작용을 예측하고, 치료적 잠재력이 있는 새로운 화합물을 설계합니다. 머신 러닝과 데이터 마이닝 기술을 통해 AI는 약물 개발 프로세스를 가속화하고, 분자 선택을 최적화하고, 비용을 절감합니다. 표적 식별, 리드 최적화, 독성 예측을 향상시켜 제약 연구에 혁명을 일으키고 생명을 구하는 약물의 전달을 가속화합니다.            

약물 발견 시장 역학에서의 인공지능(AI)

운전자

• 가속 약물 발견 프로세스

AI expedites the drug discovery process by analyzing vast datasets, predicting molecular interactions, and identifying potential drug candidates more rapidly than traditional methods.  For instance, Atomwise, using AI-powered virtual screening, identified a drug candidate for Ebola in just a few days, a process that typically takes months using traditional methods. This acceleration allows for quicker identification and development of promising compounds, potentially saving lives in urgent medical situations.

• Rise in Incidence of Chronic Diseases Propels Need

The surge in chronic diseases worldwide, exemplified by CDC data showing six in 10 U.S. adults affected, underscores the urgency for effective treatments. AI in drug discovery emerges as a promising solution to mitigate this health crisis. Through analyzing vast datasets, AI platforms offer insights into developing drugs targeting conditions such as heart disease and diabetes, addressing the pressing need for innovative therapies to reduce mortality rates.  

Opportunities

• Rising Collaboration and Data Sharing among Researchers

AI fosters collaboration among researchers and facilitates data sharing across institutions and companies, enabling access to diverse datasets and enhancing the collective knowledge base for drug discovery. For instance, platforms such as OpenAI's Drug Discovery, which harness AI to analyze molecular structures and predict drug properties, encourage collaborative efforts by providing a shared space for researchers to access and contribute to a vast pool of data, accelerating the pace of discovery and innovation in the pharmaceutical industry.

• Growing Demand for Personalized Medicine

AI facilitates personalized medicine by analyzing patient data, including genomics, proteomics, and clinical records, to identify biomarkers indicative of disease susceptibility and treatment response. For instance, AI-driven analysis of tumor genomic profiles can predict patient responses to specific cancer therapies, enabling tailored treatment strategies that maximize efficacy and minimize adverse effects, ultimately improving patient outcomes in oncology and beyond. 

Restraints/Challenges

• Integration with Traditional Methods Hinder Workflow

Integrating AI with traditional drug discovery methods faces hurdles in standardization, compatibility, and workflow optimization. Harmonizing AI algorithms with established experimental and computational techniques necessitates meticulous planning to ensure seamless integration, minimizing disruptions to existing workflows.   

• Data Privacy and Accessibility Limit Development

Access to proprietary data in drug discovery is restricted due to privacy, intellectual property, and regulatory constraints. This limits the availability of data for AI models, hindering their development and validation. Privacy concerns, especially regarding patient data, necessitate careful handling and compliance with regulations, further complicating data accessibility for AI-driven drug discovery initiatives.   

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In July 2021, Chief.AI introduced a pay-as-you-go AI platform for drug discovery, democratizing access to advanced AI technologies. This empowers small and medium enterprises to pinpoint breakthrough therapeutics swiftly and precisely, addressing the unpredictability of traditional drug discovery
• In January 2021, Nucleai and Debiopharm Pharma formed a collaborative agreement, permitting the latter to utilize Nucleai's AI platform for oncology drug candidates. This underscores AI's growing significance in refining drug development processes, particularly in biomarker-based therapies
• In September 2020 witnessed Atomwise securing USD 123 million in Series B financing, led by Sanabil and B Capital Group Investments. This substantial investment aims to expand Atomwise's market presence, initiate its drug discovery pipeline, and forge new partnerships with pharmaceutical firms, emphasizing AI's pivotal role in advancing artificial intelligence in drug discovery and development
• In July 2020, IBM strategically acquired WDG Automation, enriching its AI-infused automation capabilities for enterprises. This strategic move enhances IBM's capacity to deliver comprehensive AI solutions, spanning from business processes to IT operations, thereby fortifying its overall portfolio

Artificial Intelligence (AI) in Drug Discovery Market Scope

The market is segmented on the basis of application, technology, drug type, offering, indication, and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

• Novel Drug Candidates
• Drug Optimization and Repurposing Preclinical Testing and Approval
• Drug Monitoring
• Finding New Diseases Associated Targets and Pathways
• Understanding Disease Mechanisms
• Aggregating and Synthesizing Information
• Formation and Qualification of Hypotheses
• De Novo Drug Design
• Finding Drug Targets of an Old Drug
• Others

Technology

• Machine Learning
  • Supervised Learning
  • Reinforcement Learning
  • Unsupervised Learning
  • Other Machine Learning Technologies
• Deep Learning
• Natural Language Processing
• Others

Drug Type

• Small Molecule
• Large Molecule

Offering

• Software
• Services

Indication

• Immuno-Oncology
• Neurodegenerative Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Others

End Use

• Contract Research Organizations (CROs)
• Pharmaceutical and Biotechnology Companies
• Research Centers and Academic Institutes
• Others

Artificial Intelligence (AI) in Drug Discovery Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, application, technology, drug type, offering, indication, and end use as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the artificial intelligence (AI) in drug discovery market, driven by substantial research investments and widespread AI adoption in medicine development. Key players such as IBM, Google, and Microsoft strengthen the region's influence and technological advancement, catalyzing market growth significantly.

Asia-Pacific is expected to witness rapid growth in the artificial intelligence (AI) in drug discovery market due to heightened investments in research and development initiatives. The region's evolving healthcare infrastructure further accelerates market expansion, underscoring its growing influence in shaping AI applications for drug discovery.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

이 시장은 또한 자본 장비에 대한 의료 지출의 모든 국가별 성장, 시장에 대한 다양한 종류의 제품의 설치 기반, 수명선 곡선을 사용한 기술의 영향, 의료 규제 시나리오의 변화 및 시장에 미치는 영향에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2016-2021년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 약물 발견 시장 점유율 분석에서의 인공지능(AI)

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• 엔비디아 코퍼레이션(미국)
• IBM Corp. (미국)
• Atomwise Inc. (미국)
• 마이크로소프트(미국)
• Benevolent AI(영국)
• Aria Pharmaceuticals, Inc. (미국)
• DEEP GENOMICS(캐나다)
• 엑스사이언티아(영국)
• 인실리코 메디신(홍콩)
• Cyclica(캐나다)
• NuMedii, Inc. (미국)
• 엔비사제닉스(미국)
• 오우킨 주식회사(미국)
• BERG LLC(미국)
• 슈뢰딩거 주식회사(미국)
• XtalPi Inc. (중국)
• BIOAGE Inc. (미국)

SKU-52303